作为对癌症的双刃剑,隐形素的作用是癌症的双刃剑
Helia Mavaddat1,2, Abtin Fouladi3,2, Amirreza Peyrovinasab1,2
1Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Molecular biology reports
|September 30, 2025
概括
基于因克雷的糖尿病药物在癌症中发挥了双重作用,可能会增加某些癌症的风险,同时在其他癌症中提供治疗益处. 仔细考虑患者是平衡因克雷丁治疗风险和回报的关键.
科学领域:
- 内分泌学和瘤学 在内分泌学和瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像GLP-1和GIP这样的内素对于2型糖尿病的管理至关重要.
- 基于因克雷丁的疗法可能会影响胰腺β细胞的增殖,引发癌症的担忧.
研究的目的:
- 审查克素对癌症发展的多方面的影响.
- 评估瘤学中基于英克雷丁的药物的风险和治疗潜力.
主要方法:
- 临床队列研究的综合性审查.
- 在体内和体外研究的分析.
- 对分子和细胞机制的批判性检查.
主要成果:
- 与胰腺癌,甲状腺癌,胆管癌和结直肠癌的风险增加有关,特别是在易患的个体中.
- 在前列腺,乳腺和卵巢癌中观察到抗癌作用,包括抑制增殖和诱导亡.
- 机制包括瘤生长抑制,亡诱导和免疫反应调节.
结论:
- 基于因克雷的药物在特定组织和敏感个体中存在潜在的癌症风险.
- 在治疗其他类型的癌症中,因克雷丁的治疗潜力是有希望的.
- 通过仔细,针对患者的具体评估,因克雷丁治疗的益处可能会超过风险.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Psychoneuroimmunology: Diabetes and Cancer
459
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
459
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


